






Antidiabetic Active Pharmaceutical Ingredients (APIs) and impurities


















ALL LGC
PRODUCTS
LINK DIRECTLY
TO WEBSHOP















Antidiabetic APIs and impurities

Code	Product	CAS No.	CS	Unit	
Buformin Hydrochloride					
MM1843.00	Buformin Hydrochloride	1190-53-0		100mg	
Carbutamide					
MM1856.00	Carbutamide	339-43-5		100mg	
Chlorpropamide					
MM1635.00	Chlorpropamide	94-20-2		250mg	
MM1635.01	Imp. B (EP): 1,3-Dipropylurea	623-95-0		100mg	
Dapagliflozin (2S)-1,2-Propanediol Monohydrate					
MM3611.00	Dapagliflozin (2S)-1,2-Propanediol Monohydrate	960404-48-2		50mg	
MM3611.04	Dapagliflozin	461432-26-8		100mg	
MM3611.01	4-Bromo-1-chloro-2-(4-ethoxybenzyl)benzene	461432-23-5		100mg	
MM3611.02	Dapagliflozin Tetraacetate ([[(2R,3R,4R,5S,6S)-3,4,5-Triacetoxy-6-[4-chloro-3-(4-ethoxybenzyl)phenyl]tetrahydropyran-2-yl]methyl] Acetate)	461432-25-7		100mg	
MM3611.03	(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)-2-methoxy-tetrahydropyran-3,4,5-triol	714269-57-5		100mg	
Glibenclamide					
MM0008.00	Glibenclamide	10238-21-8		500mg	
MM0008.01	Imp. A (EP): 5-Chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide	16673-34-0		100mg	
MM0008.02	Imp. B (EP): Methyl [[4-[2-[(5-Chloro-2-methoxybenzoyl)amino]ethyl]phenyl]sulphonyl]carbamate	21165-77-5		100mg	
MM0942.09	Imp. C (EP): 1-Cyclohexyl-3-[[4-[2-[(cyclohexylcarbamoyl)amino]ethyl]phenyl]sulfonyl]urea (N-(Cyclohexylcarbamoyl)-4-[2-[(cyclohexylcarbamoyl)amino]ethyl]benzenesulphonamide)	10079-35-3		100mg	
MM0008.07	Imp. D (EP): 1-Butyl-3-[[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]urea (1-[[4-[2-[(5-Chloro-2-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]-3-butylurea)	38160-73-5		50mg	
MM0008.08	Imp. E (EP): 1-Cyclohexyl-3-[[4-[2-[(3,5-dichloro-2-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]urea (1-[[4-[2-[(3,5-Dichloro-2-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]-3-cyclohexylurea)	57334-89-1		50mg	









Antidiabetic APIs and impurities

Code	Product	CAS No.	CS	Unit	
MM0008.03	5-Chloro-2-methoxybenzoic Acid	3438-16-2		100mg	
MM0008.04	5-Chloro-N-(2-phenylethyl)-2-methoxybenzamide	33924-49-1		100mg	
Gliclazide					
MM0325.00	Gliclazide	21187-98-4		500mg	
MM0325.01	Imp. A (EP): 4-Methylbenzenesulphonamide	70-55-3		100mg	
MM0325.02	Imp. B (EP): 2-Nitroso-octahydrocyclopenta[c]pyrrole	54786-86-6		100mg	
MM0325.03	Imp. C (EP): Ethyl [(4-Methylphenyl)sulphonyl]-carbamate	5577-13-9		100mg	
MM0325.06	Imp. F (EP): 1-(Hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-[(2-methylphenyl)sulphonyl]urea	1076198-18-9		100mg	
MM0325.09	Methyl N-Methyl-p-tolylsulphoncarbamate	32258-50-7		100mg	
MM0325.10	Octahydrocyclopenta[c]pyrrole Hydrochloride	112626-50-3		100mg	
MM0325.11	N-Carbamoyl-2-methylbenzenesulfonamide (N-(Aminocarbonyl)-2-methylbenzenesulfonamide)	39051-77-9		100mg	
Glimepiride					
MM0647.00	Glimepiride	93479-97-1		100mg	
MM0647.02	Imp. A (EP): 1-[[4-[2-[[[(3-Ethyl-4-methyl-2-oxo-2,3-dihydro-1H-pyrrol-1-yl)carbonyl]-amino]ethyl]phenyl]sulphonyl]-3-(cis-4-methylcyclohexyl)urea (cis-Glimepiride)	684286-46-2		100mg	
MM0647.01	Imp. B (EP): 3-Ethyl-4-methyl-2-oxo-N-[2-(4-sulphamoylphenyl)ethyl]-2,3-dihydro-1H-pyrrole-1-carboxamide (Glimepiride Sulphonamide)	119018-29-0		100mg	
MM0647.03	Imp. C (EP): Methyl [[4-[2-[[[(3-Ethyl-4-methyl-2-oxo-2,3-dihydro-1H-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulphonyl]carbamate (Glimepiride Carbamate)	119018-30-3		100mg	
MM0647.04	Imp. D (EP): 1-[[3-[2-[[[(3-Ethyl-4-methyl-2-oxo-2,3-dihydro-1H-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulphonyl]-3-(trans-4-methylcyclohexyl)-urea	791104-62-6		100mg	
MM0647.08	cis-4-Methylcyclohexylamine Hydrochloride	33483-66-8		100mg	
Glipizide					
MM0942.01	Imp. A (EP): 5-Methyl-N-[2-(4-sulphamoylphenyl)ethyl]pyrazine-2-carboxamide	33288-71-0		100mg	
















Antidiabetic APIs and impurities

Code	Product	CAS No.	CS	Unit	
MM0678.03	Imp. B (EP): Cyclohexanamine	108-91-8		100mg	
MM0942.04	Imp. D (EP): 6-Methyl-N-[2-(4-sulphamoylphenyl)ethyl]pyrazine-2-carboxamide	n/a		100mg	
MM0942.05	Imp. E (EP): 1-Cyclohexyl-3-[[4-[2-[[[(6-methylpyrazin-2-yl)carbonyl]amino]ethyl]phenyl]sulphonyl]urea	66375-96-0		100mg	
MM0942.06	Imp. F (EP): Ethyl [2-(4-Sulphamoylphenyl)ethyl]carbamate	192118-08-4		100mg	
MM0942.07	Imp. G (EP): Methyl [[4-[2-[[[(5-Methylpyrazin-2-yl)carbonyl]amino]ethyl]phenyl]sulphonyl]carbamate	33288-74-3		100mg	
MM0942.08	Imp. H (EP): 4-[2-[(Cyclohexylcarbamoyl)amino]ethyl]benzenesulphonamide	10080-05-4		100mg	
MM0942.09	Imp. I (EP): N-(Cyclohexylcarbamoyl)-4-[2-[(cyclohexylcarbamoyl)amino]ethyl]benzenesulphonamide	10079-35-3		100mg	
Gliquidone					
MM3094.00	Gliquidone	33342-05-1		250mg	
Glymidine Sodium					
MM1964.00	Glymidine Sodium	3459-20-9		50mg	
Linagliptin					
MM3412.00	Linagliptin	668270-12-0		250mg	
Metformin Hydrochloride					
MM0056.00	Metformin Hydrochloride	1115-70-4		500mg	
MM0056.01	Imp. A (EP): Cyanoguanidine	461-58-5		100mg	
MM0056.07	Imp. B (EP) as Nitrate: (4,6-Diamino-1,3,5-triazin-2-yl)guanidine Nitrate	3553-49-9		100mg	
MM0056.03	Imp. C (EP): N,N-Dimethyl-1,3,5-triazine-2,4,6-triamine	1985-46-2		100mg	
MM0056.04	Imp. D (EP): 1,3,5-Triazine-2,4,6-triamine (Melamine)	108-78-1		100mg	
MM0056.05	Imp. E (EP) as Hydrochloride: 1-Methylbiguanide Hydrochloride	1674-62-0		100mg	
MM0056.06	Imp. F (EP) as Hydrochloride: N-Methylmethanamine Hydrochloride	506-59-2		100mg	

Antidiabetic APIs and impurities

Code	Product	CAS No.	CS	Unit	
Nateglinide					
MM0847.00	Nateglinide	105816-04-4		100mg	
MM0847.02	Imp. A (EP): <i>trans</i> -4-(1-Methylethyl)cyclohexanecarboxylic Acid	7077-05-6		100mg	
MM0847.03	Imp. B (EP): <i>N</i> -[[<i>trans</i> -4-(1-Methylethyl)cyclohexyl]carbonyl]-L-phenylalanine (Nateglinide L-Phenylalanine Isomer)	105816-05-5		50mg	
MM1560.00	Imp. D (EP): (2 <i>S</i>)-2-Amino-3-phenylpropanoic Acid (Phenylalanine)	63-91-2		250mg	
MM0847.04	Imp. E (EP): <i>N</i> -[[<i>trans</i> -4-Ethylcyclohexyl]carbonyl]-D-phenylalanine (Nateglinide Ethyl Analog)	105746-45-0		50mg	
MM0847.09	Imp. F (EP) as Dicyclohexylammonium Salt: <i>N</i> -[[<i>trans</i> -4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt)	n/a		50mg	
MM0847.06	Imp. G (EP): Ethyl <i>N</i> -[[<i>trans</i> -4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalaninate (Nateglinide Ethyl Ester)	187728-85-4		50mg	
MM0314.03	Phenylalanine	150-30-1		100mg	
MM0847.10	Nateglinide Methyl Ester	105746-47-2		100mg	
MM0847.11	Nateglinide Isopropyl Ester	n/a		100mg	
Phenformin Hydrochloride					
MM1574.00	Phenformin Hydrochloride	834-28-6		250mg	
Pioglitazone Hydrochloride					
MM0616.00	Pioglitazone Hydrochloride	112529-15-4		100mg	
MM0616.06	Imp. C (EP): (5 <i>RS</i>)-5-[[4-[2-(5-Ethylpyridin-2-yl)ethoxy]phenyl]methyl]-3-[2-(5-ethylpyridin-2-yl)ethyl]thiazolidine-2,4-dione	952188-00-0		50mg	
MM0616.08	Imp. E (EP): Ethyl 3-[4-[2-(5-Ethylpyridin-2-yl)ethoxy]phenyl]propanoate	868754-42-1		50mg	
MM0616.04	5-[4-[2-(5-Ethylpyridin-2-yl)ethoxy]benzyl]-2-iminothiazolidin-4-one	105355-26-8		100mg	

Antidiabetic APIs and impurities

Code	Product	CAS No.	CS	Unit	
MM0616.09	Pioglitazone N-Oxide	145350-09-0		100mg	
Repaglinide					
MM0944.00	Repaglinide	135062-02-1		100mg	
MM0944.02	Imp. B (EP): [3-Ethoxy-4-(ethoxycarbonyl)-phenyl]acetic Acid	99469-99-5		100mg	
MM0944.01	Imp. C (EP) as N-Acetyl-L-glutamate: (1S)-3-Methyl-1-[2-(piperidin-1-yl)phenyl]butan-1-amine N-Acetyl-L-glutamate	219921-94-5		100mg	
MM0944.05	Imp. D (EP): Ethyl 2-Ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoate (Repaglinide Ethyl Ester)	147770-06-7		100mg	
MM0944.07	Repaglinide Methyl Ester	800365-89-3		100mg	
MM0944.08	Repaglinide Isopropyl Ester	n/a		100mg	
MM0944.10	O-Desethylrepaglinide (2-Hydroxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidiny)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid)	1809091-07-3		100mg	
MM0944.12	Repaglinide Anhydride	n/a		100mg	
Rosiglitazone Maleate					
MM0522.01	Rosiglitazone Maleate	155141-29-0		100mg	
MM0522.04	Imp. A (Pharmeuropa): 3-[4-[2-[Methyl(pyridin-2-yl)amino]ethoxy]phenyl]propanamide	n/a		50mg	
MM0522.02	2-[N-Methyl-N-(pyridin-2-yl)amino]ethanol	122321-04-4		100mg	
MM0522.06	5-[4-[2-[Methyl(pyridin-2-yl)amino]ethoxy]benzyl]-2-imino-1,3-thiazolidin-4-one	329249-53-8		100mg	
Saxagliptin Hydrochloride					
MM3377.00	Saxagliptin Hydrochloride	709031-78-7		100mg	
MM3377.01	Saxagliptin	361442-04-8		100mg	
Sitagliptin Phosphate Monohydrate					
MM3378.00	Sitagliptin Phosphate Monohydrate	654671-77-9		250mg	

Antidiabetic APIs and impurities

Code	Product	CAS No.	CS	Unit	
Tolazamide					
MM1344.00	Tolazamide	1156-19-0		100mg	
Tolbutamide					
MM1089.00	Tolbutamide	64-77-7		100mg	
MM0325.01	Imp. A (EP): (4-Methylphenyl)sulfonamide (Toluenesulfonamide; 4-Methylbenzene-sulfonamide)	70-55-3		100mg	
Vildagliptin					
MM3564.00	Vildagliptin	274901-16-5		250mg	
MM0564.00	Amantadine Hydrochloride	665-66-7		500mg	

For further information, or if you require substances or materials not currently listed please contact one of our local sales offices:

Brazil

Tel: +55 12 3302 5880
Email: bz@lgcstandards.com

Bulgaria

Tel: +359 (0)2 971 4955
Email: bg@lgcstandards.com

China

Tel: +86 400 921 6156
Email: infochina@lgcgroup.com

France

Tel: +33 (0)3 88 04 82 82
Email: fr@lgcstandards.com

Germany

Tel: +49 (0)281 9887 0
Email: de@lgcstandards.com

Hungary

Tel: +49 (0)281 9887 0
Email: de@lgcstandards.com

India

Tel: +91(0)9082974025
Email: india@lgcgroup.com

Ireland

Tel: +44 (0)20 8943 8480
Email: uksales@lgcstandards.com

Italy

Tel: +39 02 2247 6412
Email: it@lgcstandards.com

Middle East

Tel: +49 (0)281 9887 0
Email: global.sales@lgcgroup.com

Netherlands

Tel: +49 (0)281 9887 0
Email: de@lgcstandards.com

Nordic countries

Tel: +49 (0)281 9887 0
Email: de@lgcstandards.com

Poland

Tel: +48 22 751 31 40
Email: pl@lgcstandards.com

Romania

Tel: +40 364 116890
Email: ro@lgcstandards.com

Russia

Tel: +7 812 777 04 88
Email: ru@lgcgroup.com

South Africa

Tel: +27 (0)11 466 4321
Email: sales.za@lgcgroup.com

Spain

Tel: +34 (0)93 308 4181
Email: es@lgcstandards.com

Turkey

Tel: +90 530 880 33 90
Email: tur@lgcstandards.com

UK - Reference materials

Tel: +44 (0)20 8943 8480
Email: uksales@lgcstandards.com

UK - Proficiency testing

Tel: +44 (0)161 762 2500
Email: uksales@lgcstandards.com

USA + Canada

Tel: +1-855-LGC-USA1 (toll-free)
Email: lgcusa@lgcstandards.com

Export queries

Tel: +49 (0)281 9887 250
Email: global.sales@lgcgroup.com

**Browse and buy reference standards online
at lgcstandards.com**



lgcstandards.com
Science for a safer world

**Brazil • Bulgaria • China • France • Germany • Hungary • India • Ireland • Italy • Netherlands
Nordic countries • Poland • Romania • Russia • South Africa • Spain • Turkey • United Kingdom • USA**

All trademarks and registered trademarks mentioned herein are the property of their respective owners. All other trademarks and registered trademarks are the property of LGC and its subsidiaries. Specifications, terms and pricing are subject to change. Not all products are available in all countries. Please consult your local sales representative for details. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or any retrieval system, without the written permission of the copyright holder.
© LGC Limited, 2017. All rights reserved. STD/0042/EA/0717